Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)

NCT04317040 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

234

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronavirus Disease 2019 (COVID-19)

Interventions

DRUG: Efprezimod alfa
DRUG: Placebo

Sponsor

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)